Degludec

ApprovedSmall molecule

Eli Lilly

Degludec is one of 61 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic KetoacidosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

Type 1 DiabetesActive, not recruiting

Diabetes Mellitus, Type 2Recruiting

Diabetic KetoacidosisPreclinical

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Type 1 DiabetesApproved

Active, not recruiting

Diabetes Mellitus, Type 2Phase 2

Recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Degludec

Eli Lilly

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 8

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 9

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Diabetes Mellitus, Type 2

NCT07215312

Clinical

Trials by Indication[1]

Diabetic Ketoacidosis1 trial

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Terminated·HHennepin Healthcare Research Institute·N/A·NCT03001323·27 enrolled

Type 1 Diabetes1 trial

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Unknown status·—·Phase 4·NCT04664764·60 enrolled

Cardiovascular1 trial

Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

Completed·UUniversity of Split, School of Medicine·Phase 4·NCT04692415·25 enrolled

Type 2 Diabetes1 trial

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT03336528·180 enrolled

Diabetes Mellitus, Type 21 trial

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07215312·100 enrolled

1 more indication

Unspecified1 trial

Degludec Glargine U300 Hospital Study

Completed·MMedanta, The Medicity, India·N/A·NCT05036876·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Degludec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Degludec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Degludec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

Degludec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Diabetic Ketoacidosis1 trial

Type 1 Diabetes1 trial

Cardiovascular1 trial

Type 2 Diabetes1 trial

Diabetes Mellitus, Type 21 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News